Magdeburg, Germany

Peter Röhnert


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Peter Röhnert

Introduction

Peter Röhnert is a notable inventor based in Magdeburg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases. With a total of 2 patents, Röhnert's work focuses on innovative drug compositions that aim to improve patient outcomes.

Latest Patents

Röhnert's latest patents include a drug preparation comprising α-lipoic acid, ambroxol, and/or inhibitors of the angiotensin-converting enzyme (ACE). This invention is designed for the treatment of neurodegenerative diseases, providing a method for using the composition to prevent and treat these conditions. Another significant patent involves the use of inhibitors of enzymes with activities of amino peptidase N and/or dipeptidyl peptidase IV. This invention addresses the treatment of neurodegenerative diseases by targeting mis-folded proteins that contribute to pathogenesis and inflammatory reactions.

Career Highlights

Throughout his career, Röhnert has worked with various companies, including Keyneurotek Pharmaceuticals AG and Key Neurotek AG. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.

Collaborations

Röhnert has collaborated with notable colleagues such as Frank Striggow and Klaus G Reymann. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Peter Röhnert's contributions to the field of pharmaceuticals, particularly in neurodegenerative disease treatment, highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to advancing medical science and providing new therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…